NCT03531684 is a Phase 2 clinical trial of MMFS-205-SR in Alzheimer Disease, sponsored by Neurocentria, Inc..

Who is sponsoring NCT03531684?

NCT03531684 is sponsored by Neurocentria, Inc..

What drugs are being tested in NCT03531684?

Interventions in NCT03531684: MMFS-205-SR, Placebo.

What condition does NCT03531684 study?

NCT03531684 studies Alzheimer Disease.

Is NCT03531684 still recruiting?

NCT03531684 is currently completed. Last updated 9 September 2020.

Last reviewed 2020-09-09 · How we verify

NCT03531684

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of MMFS in Early AD

Completed Phase 2 Last updated 9 September 2020

What this trial tests

Phase 2 trial testing MMFS-205-SR in Alzheimer Disease in 10 participants. Completed in 22 April 2020.

Timeline

20 March 2018

Primary endpoint
22 April 2020

22 April 2020

Quick facts

Lead sponsor	Neurocentria, Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	other
Enrollment	10
Start date	20 March 2018
Primary completion	22 April 2020
Estimated completion	22 April 2020
Sites	1 location across United States

Drugs / interventions tested

MMFS-205-SR
Placebo

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →

Sponsor

Neurocentria, Inc. — full company profile →

Who can join

Adults 55 to 85, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to evaluate the safety and efficacy of MMFS for improving cognition and global function in patients with probable Early Alzheimer's disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other Neurocentria, Inc. trials

Trials by the same sponsor.

NCT06673368 — A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT · Phase 2 · terminated
NCT06215144 — Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD · Phase 2, PHASE3 · terminated
NCT05683249 — Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD) · Phase 2, PHASE3 · completed
NCT03601169 — Comparison of MMFS Dosages in Older Adults · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03531684 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Neurocentria, Inc.
Last refreshed: 9 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03531684.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing